IGM updated its IPO filing on 9/17/19. In the amended filing, the Mountain View, CA based biotech said it may raise up to $213 million and offer 10,937,500 shares. IGM will trade on NASDAQ under... read more
CINs are becoming a primary point of engagement for IDNs and are becoming more crucial to population health management and value-based contracts. To this end, CINs are becoming building blocks for... read more
Satsuma Pharmaceuticals file the paperwork for an $80 million IPO on 9/11/19. The company is developing a nasal delivery form of dihydroergotamine mesylate (DHE) for treating migraine headaches.... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,